Spironolactone
medication that is primarily used to treat fluid build-up due to heart failure, liver scarring, or kidney disease
Spironolactone, sold under the brand name Aldactone among others, is classed as a diuretic medication. It can be used to treat fluid build-up due to liver disease or kidney disease. It is also used to reduce risk of disease progression, hospitalization, and death due to some types of heart failure. Other uses include acne and excessive hair growth in women, low blood potassium that does not improve with supplementation, high blood pressure that is difficult to treat, and early puberty in boys. It is also used to block the effects of testosterone as a part of feminizing hormone therapy. Spironolactone is usually available in tablets, taken by mouth, though topical forms are also available.
Common side effects include electrolyte abnormalities, particularly high blood potassium, nausea, vomiting, headache, rashes, and a decreased desire for sex. In those with liver or kidney problems, extra care should be taken.
If taken during pregnancy, some animal studies suggest that spironolactone may affect the development of sex organs in babies. While this has not occurred in the few human studies available, women who are pregnant or considering pregnancy should discuss spironolactone use with their doctor due to the theoretical risk.
“Spironolactone” enters the record as medication that is primarily used to treat fluid build-up due to heart failure, liver scarring, or kidney disease. Crown Archives preserves that source wording while asking what Spironolactone, medication and primarily can confirm, complicate or overturn.
Why this record matters
“Spironolactone” is worth following because a concise public description often conceals a longer documentary argument. Here, Spironolactone, medication and primarily provides the most credible route into that argument.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 16, 2026. The linked authority identifier is Q422188. The Library of Congress control number is sh85126790. 1 of 1 selected statements include explicit references; 1 carry qualifiers and 0 use preferred rank.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Spironolactone”, its source revision and the description used here.
- Expand the search: follow Spironolactone primary sources, Spironolactone archive and Spironolactone research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Spironolactone”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Spironolactone” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.